Most Read Articles
11 days ago
Increased serum levels of C-X-C motif chemokine (CXCL)-11, CXCL-9, CXCL-10 and interferon (IFN)-γ are associated with clinical manifestations of adult-onset Still’s disease (AOSD), reports a new study.
3 days ago
At a recent lunch symposium during the 14th Annual Scientific Meeting of the Malaysian Society of Hypertension, Dr Chow Yok Wai spoke on the importance of patient adherence in the management of hypertension, highlighting the role of combination therapy in improving treatment outcomes.
5 days ago
Myopia is associated with depressive symptoms in Chinese adults, a new population-based study shows.
6 days ago
Chronic obstructive pulmonary disease (COPD) is currently the 10th commonest cause of death in Singapore, with a disease burden of 5.9 percent according to a 2015 population-based survey (EPIC-Asia survey) in Singapore. Pearl Toh spoke with Dr Augustine Tee, chief and senior consultant of the Department of Respiratory and Critical Care Medicine at Changi General Hospital (CGH) in Singapore, on how COPD is often underdetected in the primary care population as symptoms are not specific and diagnosis requires a combination of clinical risk factors, symptoms and spirometry testing.

Product Highlight - Keytruda

5 months ago
KEYTRUDA – Pembrolizumab 100 mg/4 mL soln for inj – Merck Sharp & Dohme
  • Efficient: Significant efficacy and durable response. 41% ORR whose tumors expressed ≥50% PD-L1 and 84% of patients OR had ongoing responses1,2
  • Predictive: In NSCLC, testing for PD-L1 expression helps to identify patients most likely to respond and to develop a patient’s treatment algorithm1
  • Practical: Convenience dosing of 2 mg/kg administered as an intravenous infusion over 30 minutes every 3 weeks3
  • Manageable Safety Profile: Most of the common adverse reactions were grade 1 or 24
  • PD-1 Blockade: Selectively targets PD-1 directly on the T-cell for the complete PD-1 pathway blockade of both PD-L1 and PD-L2 ligands4

References:
1. Supplement to: Garon EB et.al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl JMed. 2015; 372: 2018-2028
2. Garon EB et.al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl JMed. 2015; 372: 2018-2028
3. Keytruda pack insert LPC-MK 3475-IV-122015
4. Herbst RS et.al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small cell lung cancer (KEYNOTE-010): a randomized controlled trial. Lancet. 2016; 387 (10027): 1540-1550


Further and safety information is available in section 9d, New In This Issue and mims.com.
Full prescribing information is available upon request.
ONCO-1199329-0000 10/16

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
11 days ago
Increased serum levels of C-X-C motif chemokine (CXCL)-11, CXCL-9, CXCL-10 and interferon (IFN)-γ are associated with clinical manifestations of adult-onset Still’s disease (AOSD), reports a new study.
3 days ago
At a recent lunch symposium during the 14th Annual Scientific Meeting of the Malaysian Society of Hypertension, Dr Chow Yok Wai spoke on the importance of patient adherence in the management of hypertension, highlighting the role of combination therapy in improving treatment outcomes.
5 days ago
Myopia is associated with depressive symptoms in Chinese adults, a new population-based study shows.
6 days ago
Chronic obstructive pulmonary disease (COPD) is currently the 10th commonest cause of death in Singapore, with a disease burden of 5.9 percent according to a 2015 population-based survey (EPIC-Asia survey) in Singapore. Pearl Toh spoke with Dr Augustine Tee, chief and senior consultant of the Department of Respiratory and Critical Care Medicine at Changi General Hospital (CGH) in Singapore, on how COPD is often underdetected in the primary care population as symptoms are not specific and diagnosis requires a combination of clinical risk factors, symptoms and spirometry testing.